Sumitomo Pharma Selected as Highest Rating A-List Company by CDP
for Two Consecutive Years in the Category of Climate Change in the CDP 2025
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that it has been selected by CDP, a global environmental non-profit organization, as the highest A-List company for two consecutive years in the category of "climate change" in the CDP 2025, in recognition of its efforts and measures against climate change.
Sumitomo Pharma Group defines the practice of its Mission, "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," that contributes to the realization of a sustainable society and leads to the sustained enhancement of its corporate value as "Sustainability Management," and has set "Promotion of environmental initiatives" as one of our Material Issues for our Sustainability Management.
Environmental issues such as climate change are serious global problems that threaten the health and wellbeing of people worldwide. Sumitomo Pharma Group will continually contribute to solving these problems through reducing GHG emissions and other environmental initiatives as well as to realizing a sustainable society, thereby enhancing sustained corporate value.
Please visit https://www.sumitomo-pharma.com/sustainability/environment/ to find out our environmental initiatives.
【Reference】
CDP
CDP is a global non-profit that runs the world's only independent environmental
1
disclosure system. Partnering with leaders in enterprise, capital, policy and science, we surface the information needed to enable Earth-positive decisions.
Please visit https://www.cdp.net/en to find out more.
Sumitomo Pharma Co. Ltd. published this content on December 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 15, 2025 at 02:11 UTC.
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
